Tempus AI and Gilead Sciences Expand Strategic Oncology Partnership

Tempus AI, Inc. (TEM) has announced an expansion of its multi-year strategic partnership with Gilead Sciences, Inc. (GILD), focusing on the optimization of oncology drug development. The collaboration aims to leverage advanced data analytics to refine the discovery and development process for cancer treatments. The agreement centers on the integration of Tempus' AI-driven Lens platform across Gilead's enterprise. By leveraging real-world data and multimodal biological insights, the collaboration is designed to help researchers navigate billions of data points to isolate meaningful biological signals, thereby increasing the probability of success for new medicines. Under the expanded terms, Gilead will gain access to broader datasets across multiple indications and utilize dedicated analytical services provided by Tempus. This integration allows Gilead to combine its internal scientific expertise with Tempus' specialized data capabilities to maximize the generation of key clinical insights. For Tempus AI, the expansion reinforces the commercial viability and scalability of its Lens platform within the pharmaceutical industry. For Gilead, the move represents a strategic commitment to AI-driven R&D to reduce the inherent risks and costs associated with oncology pipeline development.